Sanofi India Limited has informed the Exchange regarding Cessation of Mr Rodolfo Hrosz as Managing Director of the company w.e.f. April 30, 2025.

CEO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹6080.10

prior close

₹6159.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+3.4%-1.3% vs market

Pharmaceuticals peers, median of 147sector+2.2%-0.1% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-0.8

15m

-1.1

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.1+3.4-1.3+2.2-0.1

Next day

+1.6+6.8-5.2+5.2-3.7

+2.1+7.7-5.6+6.0-3.9

+2.1+8.5-6.3+6.9-4.7

+3.9+10.1-6.2+7.6-3.7

+4.8+11.0-6.2+7.9-3.2

+8.5+11.5-3.0+9.6-1.1

15d

-4.9+6.0-10.9+4.0-8.9

-3.7+9.8-13.5+5.3-9.0

+1.5+22.9-21.4+11.8-10.3

-2.9+22.6-25.5+11.7-14.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India has informed the stock exchange that Mr. Rodolfo Hrosz will cease to be the Managing Director of the company with effect from April 30, 2025. No reason has been disclosed in this filing, and no successor has been announced. The Managing Director is the highest executive role in the company, equivalent to the CEO. This is a key managerial personnel change at the leadership level.

Likely market impact

Investors should watch for a formal announcement regarding succession, as leadership transitions at the MD/CEO level can create short-term uncertainty around strategy and continuity. The stock may see mild volatility until a replacement is named.